[HTML][HTML] The role of clopidogrel in 2020: a reappraisal
G Patti, G Micieli, C Cimminiello… - Cardiovascular …, 2020 - hindawi.com
Antiplatelet therapy is the mainstay of treatment and secondary prevention of cardiovascular
disease (CVD), including acute coronary syndrome (ACS), transient ischemic attack (TIA) or …
disease (CVD), including acute coronary syndrome (ACS), transient ischemic attack (TIA) or …
Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes …
Aims The aim of this study was to determine the effect of ticagrelor monotherapy on clinically
relevant bleeding and major ischaemic events in relation to clinical presentation with and …
relevant bleeding and major ischaemic events in relation to clinical presentation with and …
Acute coronary syndrome, antiplatelet therapy, and bleeding: a clinical perspective
G Tersalvi, L Biasco, GM Cioffi… - Journal of clinical medicine, 2020 - mdpi.com
Inhibition of platelet function by means of dual antiplatelet therapy (DAPT) is the cornerstone
of treatment of acute coronary syndrome (ACS). While preventing ischemic recurrences …
of treatment of acute coronary syndrome (ACS). While preventing ischemic recurrences …
Characterization of the average daily ischemic and bleeding risk after primary PCI for STEMI
Background: The risk of recurrent ischemic and bleeding events after primary percutaneous
coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) may not …
coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) may not …
Abbreviated or Standard Dual Antiplatelet Therapy by Sex in Patients at High Bleeding Risk: A Prespecified Secondary Analysis of a Randomized Clinical Trial
Importance Abbreviated dual antiplatelet therapy (DAPT) reduces bleeding with no increase
in ischemic events in patients at high bleeding risk (HBR) undergoing percutaneous …
in ischemic events in patients at high bleeding risk (HBR) undergoing percutaneous …
A practical guide on how to handle patients with bleeding events while on oral antithrombotic treatment
ME Gimbel, SCS Minderhoud, JM ten Berg - Netherlands Heart Journal, 2018 - Springer
Bleeding is a feared complication in patients who are treated with antithrombotic therapy
(oral anticoagulation or antiplatelet therapy). Management of antithrombotic therapy after …
(oral anticoagulation or antiplatelet therapy). Management of antithrombotic therapy after …
Relationship between CHA2DS2-VASc score, coronary artery disease severity, residual platelet reactivity and long-term clinical outcomes in patients with acute …
F Scudiero, C Zocchi, E De Vito, G Tarantini… - International journal of …, 2018 - Elsevier
Abstract Background The CHA 2 DS 2-VASc score predicts stroke risk in patients with atrial
fibrillation, but recently has been reported to have a prognostic role even in patients with …
fibrillation, but recently has been reported to have a prognostic role even in patients with …
[HTML][HTML] High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from …
Background The prospective observational CHANGE DAPT study compared clopidogrel
versus ticagrelor-based dual antiplatelet (DAPT) regimens in consecutive patients with acute …
versus ticagrelor-based dual antiplatelet (DAPT) regimens in consecutive patients with acute …
Gender-related differences in antiplatelet therapy and impact on 1-year clinical outcome in patients presenting with ACS: the START ANTIPLATELET registry
P Cirillo, L Di Serafino, G Patti, E Antonucci… - …, 2019 - journals.sagepub.com
We investigated whether gender influences antiplatelet treatment in patients with acute
coronary syndrome (ACS). The primary end point was major adverse cardiac and …
coronary syndrome (ACS). The primary end point was major adverse cardiac and …
Associations between complex PCI and prasugrel or clopidogrel use in patients with acute coronary syndrome who undergo PCI: from the PROMETHEUS study
Abstract Background Potent P2Y 12 inhibitors might offer enhanced benefit against
thrombotic events in complex percutaneous coronary intervention (PCI). We examined …
thrombotic events in complex percutaneous coronary intervention (PCI). We examined …